% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Michiels:153313, author = {Michiels, Emiel and Roose, Kenny and Gallardo, Rodrigo and Khodaparast, Ladan and Khodaparast, Laleh and van der Kant, Rob and Siemons, Maxime and Houben, Bert and Ramakers, Meine and Wilkinson, Hannah and Guerreiro, Patricia and Louros, Nikolaos and Kaptein, Suzanne J F and Ibañez, Lorena Itatí and Smet, Anouk and Baatsen, Pieter and Liu, Shu and Vorberg, Ina and Bormans, Guy and Neyts, Johan and Saelens, Xavier and Rousseau, Frederic and Schymkowitz, Joost}, title = {{R}everse engineering synthetic antiviral amyloids.}, journal = {Nature Communications}, volume = {11}, number = {1}, issn = {2041-1723}, address = {[London]}, publisher = {Nature Publishing Group UK}, reportid = {DZNE-2020-01310}, pages = {2832}, year = {2020}, abstract = {Human amyloids have been shown to interact with viruses and interfere with viral replication. Based on this observation, we employed a synthetic biology approach in which we engineered virus-specific amyloids against influenza A and Zika proteins. Each amyloid shares a homologous aggregation-prone fragment with a specific viral target protein. For influenza we demonstrate that a designer amyloid against PB2 accumulates in influenza A-infected tissue in vivo. Moreover, this amyloid acts specifically against influenza A and its common PB2 polymorphisms, but not influenza B, which lacks the homologous fragment. Our model amyloid demonstrates that the sequence specificity of amyloid interactions has the capacity to tune amyloid-virus interactions while allowing for the flexibility to maintain activity on evolutionary diverging variants.}, keywords = {Amyloid: genetics / Amyloid: pharmacology / Amyloid: therapeutic use / Animals / Antiviral Agents: pharmacology / Antiviral Agents: therapeutic use / Disease Models, Animal / Dogs / Female / HEK293 Cells / Host-Pathogen Interactions: drug effects / Humans / Influenza A virus: drug effects / Influenza A virus: genetics / Influenza A virus: pathogenicity / Influenza, Human: drug therapy / Influenza, Human: virology / Madin Darby Canine Kidney Cells / Mice / Polymorphism, Genetic / Recombinant Proteins: genetics / Recombinant Proteins: pharmacology / Recombinant Proteins: therapeutic use / Reverse Genetics: methods / Synthetic Biology: methods / Viral Proteins: genetics / Viral Proteins: metabolism / Virus Replication: drug effects / Zika Virus: drug effects / Zika Virus: genetics / Zika Virus: pathogenicity / Zika Virus Infection: drug therapy / Zika Virus Infection: virology / Amyloid (NLM Chemicals) / Antiviral Agents (NLM Chemicals) / Recombinant Proteins (NLM Chemicals) / Viral Proteins (NLM Chemicals)}, cin = {AG Vorberg}, ddc = {500}, cid = {I:(DE-2719)1013004}, pnm = {342 - Disease Mechanisms and Model Systems (POF3-342)}, pid = {G:(DE-HGF)POF3-342}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:32504029}, pmc = {pmc:PMC7275043}, doi = {10.1038/s41467-020-16721-8}, url = {https://pub.dzne.de/record/153313}, }